ITOS
Price:
$14.8
Market Cap:
$540.52M
Iteos Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in the discovery and development of immuno-oncology therapeutics for patients. The company's product pipeline includes inupadenant, a small molecule antagonist of the adenosine A2AR antagonists that is in Phase 2 clinical trials; and EOS-448, an antagonist of TIGIT or T-cell immunoreceptor with Ig and ITIM domains, which is in Phase 1/2 clinical trial, as well as used to engage the Fc gamma receptor, or Fc?R to activate dendritic cells and macrophages and to promote antibody-dependent cellular cytotoxicity, or ADCC activity. Iteos Therapeutics, Inc. was founded in 2011 and is headquartered in Watertown, Massachuset...[Read more]
Industry
Biotechnology
IPO Date
2020-07-24
Stock Exchange
NASDAQ
Ticker
ITOS
According to iTeos Therapeutics, Inc.’s latest financial reports and current stock price. The company's current PE Ratio is -5.00. This represents a change of -33.94% compared to the average of -7.57 of the last 4 quarters.
The mean historical PE Ratio of iTeos Therapeutics, Inc. over the last ten years is -9.58. The current -5.00 PE Ratio has changed 5.12% with respect to the historical average. Over the past ten years (40 quarters), ITOS's PE Ratio was at its highest in in the September 2022 quarter at 180.96. The PE Ratio was at its lowest in in the March 2020 quarter at -28.82.
Average
-9.58
Median
-5.70
Minimum
-31.16
Maximum
7.64
Discovering the peaks and valleys of iTeos Therapeutics, Inc. PE Ratio, unveiling quarterly and yearly fluctuations to gain insights into the company’s financial performance and market dynamics, offering valuable data for investors and analysts alike.
Maximum Annual Increase = 274.99%
Maximum Annual PE Ratio = 7.64
Minimum Annual Increase = -148.39%
Minimum Annual PE Ratio = -31.16
Year | PE Ratio | Change |
---|---|---|
2023 | -3.48 | -148.39% |
2022 | 7.18 | -5.92% |
2021 | 7.64 | -124.50% |
2020 | -31.16 | 4.88% |
2019 | -29.71 | 274.99% |
The current PE Ratio of iTeos Therapeutics, Inc. (ITOS) is less than than its 3-year, greater than its 5-year, and greater than its 10-year historical averages
3-year avg
3.78
5-year avg
-9.91
10-year avg
-9.58
iTeos Therapeutics, Inc.’s PE Ratio is greater than Icosavax, Inc. (-8.27), greater than Mirati Therapeutics, Inc. (-5.32), greater than VectivBio Holding AG (-7.94), greater than Annexon, Inc. (-6.50), greater than Gracell Biotechnologies Inc. (-12.26), less than Theseus Pharmaceuticals, Inc. (-3.19), less than Monte Rosa Therapeutics, Inc. (-3.11), greater than Design Therapeutics, Inc. (-5.23), less than Erasca, Inc. (-3.94), greater than Apellis Pharmaceuticals, Inc. (-15.28), greater than TScan Therapeutics, Inc. (-6.03), greater than Terns Pharmaceuticals, Inc. (-6.06), greater than Day One Biopharmaceuticals, Inc. (-7.39), less than Acumen Pharmaceuticals, Inc. (-2.06), less than Amylyx Pharmaceuticals, Inc. (-0.97), greater than MoonLake Immunotherapeutics (-52.80), greater than Revolution Medicines, Inc. (-13.31), greater than Blueprint Medicines Corporation (-26.44), less than Sana Biotechnology, Inc. (-4.82), greater than Kymera Therapeutics, Inc. (-21.01),
Company | PE Ratio | Market cap |
---|---|---|
-8.27 | $769.04M | |
-5.32 | $4.12B | |
-7.94 | $1.06B | |
-6.50 | $607.51M | |
-12.26 | $989.87M | |
-3.19 | $181.50M | |
-3.11 | $349.21M | |
-5.23 | $264.42M | |
-3.94 | $807.96M | |
-15.28 | $5.00B | |
-6.03 | $294.00M | |
-6.06 | $549.60M | |
-7.39 | $1.25B | |
-2.06 | $133.38M | |
-0.97 | $161.36M | |
-52.80 | $2.89B | |
-13.31 | $6.99B | |
-26.44 | $5.47B | |
-4.82 | $1.12B | |
-21.01 | $2.89B |
One of the best ways to find valuable stocks to invest in is to build a custom made screener in your Excel or Google Sheets spreadsheet. This allows you to compare thousands of companies like iTeos Therapeutics, Inc. using the financials and key metrics that matter to you in a single view.
The easiest way to set this up is to use the Wisesheets add-on and set your spreadsheet like this:
Covering all these metrics from financial, data, dividend data, key metrics and more you can get all the data you want for over 50+ exchanges worldwide.
Get your free trial here.
The easiest way to analyze a company like iTeos Therapeutics, Inc. or any others is to create a spreadsheet model that automatically retrieves all of the stock data you need.
Using Wisesheets you can set up a spreadsheet model like this with simple spreadsheet formulas. If you change the ticker you can get all of the data automatically updated for you.
Whether you need live data, historical price data, financials, dividend data, key metrics, analyst estimates, or anything else...Wisesheets has you covered.
What is the PE Ratio?
How can you use the PE Ratio?
What is iTeos Therapeutics, Inc.'s PE Ratio?
How is the PE Ratio calculated for iTeos Therapeutics, Inc. (ITOS)?
What is the highest PE Ratio for iTeos Therapeutics, Inc. (ITOS)?
What is the 3-year average PE Ratio for iTeos Therapeutics, Inc. (ITOS)?
What is the 5-year average PE Ratio for iTeos Therapeutics, Inc. (ITOS)?
How does the current PE Ratio for iTeos Therapeutics, Inc. (ITOS) compare to its historical average?